GNPX · Genprex, Inc.

This 8-K discloses preclinical results—not financial or operational performance—so no income statement metrics are reported. The significance lies in mechanistic validation: GPX-002 (Pdx1/MafA gene therapy) demonstrated functional and structural restoration of β-cells in a diet-induced Type 2 diabetes mouse model, including reversal of hyperglycemia, normalization of ex-vivo insulin secretion, ultrastructural improvements in insulin granule maturation, and transcriptomic evidence of β-cell maturation. These findings support Genprex’s hypothesis that targeted pancreatic gene delivery can modify disease biology rather than merely manage symptoms. While the data are non-clinical and do not establish safety or efficacy in humans, the explicit mention of endoscopic retrograde cholangiopancreatography as a feasible human delivery route adds translational credibility. No clinical trial initiation, regulatory milestone, or partnership announcement accompanies this disclosure, and forward-looking statements emphasize substantial uncertainty regarding development timelines, regulatory approval, and commercial viability. Investors should recognize this as an early-stage scientific update—not a near-term catalyst—with material implications only for long-term pipeline de-risking.